Introduction
============

Chronic obstructive pulmonary disease (COPD) is a global epidemic and is predicted to be the fifth most widespread disease and the third-leading cause of death worldwide by 2020. [@b1-cia-8-1157]--[@b3-cia-8-1157] The incidence of COPD increases sharply with age, and is more common in males.[@b2-cia-8-1157],[@b3-cia-8-1157] Most COPD patients often have complications of multiple-organ insufficiency such as cardiac insufficiency[@b4-cia-8-1157]--[@b7-cia-8-1157] which increases mortality risk and worsens survival, thereby presenting many therapeutic challenges to health-care providers.[@b6-cia-8-1157],[@b8-cia-8-1157],[@b9-cia-8-1157]

Beta2-adrenoceptor agonists (β~2~-agonists) are typically used for COPD treatment to relieve airflow limitation and improve respiratory disorders. A recent study observed no association between β~2~-agonist therapy and mortality in patients with heart failure (HF) after adjusting for B-type natriuretic peptide (BNP).[@b10-cia-8-1157] However, for COPD patients with coexisting HF, there is some concern regarding the relationship between β~2~-agonist use and mortality in patients with cardiovascular disease. Several studies reported that regular use of β~2~-agonists can cause downregulation of myocardial β~2~-adrenoceptors, which may play an important role in onset or worsening HF.[@b11-cia-8-1157],[@b12-cia-8-1157] Au et al[@b13-cia-8-1157] showed that β~2~-agonist use was associated with an increased risk of all-cause mortality in patients with left ventricular systolic dysfunction (LVSD). Thus, the concerns and controversies make physicians reluctant to prescribe β~2~-agonists in COPD patients.

It is generally accepted that β-blockers can be used safely in patients with HF to improve LVSD[@b14-cia-8-1157] and reduce mortality.[@b15-cia-8-1157] Although a few clinical trials had suggested the safety and efficacy of β-blocker therapy in COPD patients,[@b16-cia-8-1157],[@b17-cia-8-1157] the actual use of β-blockers has remained lower than expected.[@b18-cia-8-1157],[@b19-cia-8-1157] In addition, clinicians are cautious of β-blocker use for fear of provoking bronchospasm,[@b20-cia-8-1157],[@b21-cia-8-1157] which may worsen cardiopulmonary function.

To date, there have been a considerable number of clinical trials to assess the use of β~2~-agonists and β-blockers, yet most of them have been limited by the absence of detailed data on COPD status and high-risk patients, such as the elderly. In such cases, physicians would be extremely prudent to prescribe β~2~-agonists for bronchospasm and β-blockers for tachycardia caused by cardiac insufficiency. To the best of our knowledge, COPD is an age-related disease; however, few studies have reported the effectiveness of β-blockers and β~2~-agonists in a population with COPD, particularly the elderly. Therefore, we designed the current study to assess the association between the use of β-blockers, β~2~-agonists, or a combination therapy and cardiac function, as well as all-cause mortality in elderly male COPD patients.

Methods
=======

Ethical approval of the study protocol
--------------------------------------

This study complied with the Declaration of Helsinki[@b22-cia-8-1157] and was approved by the Scientific and Ethics Review Board of the Department of Geriatrics, Chinese PLA General Hospital, Beijing, People's Republic of China. All patients enrolled in the study submitted written informed consent.

Patient enrollment
------------------

A total of 220 male COPD patients (mean age 84.1 ± 6.9 years) were retrospectively enrolled in the present trial between January 2008 and May 2011. All participants were hospitalized in the Department of Geriatrics of the Chinese PLA General Hospital during the aforementioned recruitment period. Patient information was collected and registered with the electronic database of the cardiovascular center in the same hospital. Patient recruitment was carried out by physicians from the Department of Geriatric Cardiology, PLA General Hospital, who received proper instructions from the research team on the study aims and design.

Overall, 63 patients received β~2~-agonists (salbutamol, salmeterol, or procaterol) and 112 were administered β-blockers (metoprolol, bisoprolol, or carvedilol). To evaluate the association between the use of β-blockers, β~2~-agonists, or a combination of both with cardiac function, the patients were divided into four groups on the basis of the use of β~2~-agonists and β-blockers: β~2~-agonists, β-blockers, β~2~-agonists and β-blockers, or neither (the control group).

Data on demographic variables, medication use, medical history, and current smoking status were collected. The patients' cardiovascular histories and cardiac risk factors were obtained from medical records of current or previous diagnoses and/or therapies, and included incidences of coronary heart disease, previous myocardial infarction, HF, hypertension, dyslipidemia, diabetes mellitus, renal dysfunction, and peripheral arterial occlusive disease.

Laboratory indicators, such as N-terminal fragment (NT) pro-BNP, total cholesterol, high-density-lipoprotein cholesterol, low-density-lipoprotein cholesterol (LDL-c), triglycerides, serum creatinine, and high-sensitivity C-reactive protein (HS-CRP) levels, were measured and recorded at the same time. Left ventricular ejection fraction (LVEF), left ventricular end-systolic volume, left ventricular end-diastolic volume, and shortening fraction were calculated via standard transthoracic echocardiography performed by trained doctors blinded to group allocation.

Outcomes
--------

The primary end point of the study was all-cause mortality, and eligible patients were followed up until they died (study end point) or the end of the trial duration (December 31, 2012), with a median follow-up of 22.2 months. Survival status was obtained from patient medical records.

Pulmonary function tests
------------------------

All patients underwent pulmonary function tests. Spirometric evaluations were conducted in accordance with current guidelines using established reference values. A diagnosis of COPD was based on postbronchodilator spirometric data in conjunction with a history of cough, sputum production, and/or dyspnea. COPD, as defined by the Global initiative for chronic Obstructive Lung Disease criteria,[@b1-cia-8-1157] was classified into three stages: I = mild COPD (forced expiratory volume in 1 second/forced vital capacity \[FEV~1~/FVC\] \< 0.70 and FEV~1~ ≥ 80% of the predicted FEV~1~), II = moderate COPD (FEV~1~/FVC \< 0.70 and FEV~1~ 50% ≤ FEV~1~ \< 80% of the predicted FEV~1~), and III = severe COPD (FEV~1~/FVC \< 0.70 and FEV~1~ 30% ≤ FEV~1~ \< 50% of the predicted FEV~1~).

Statistical analysis
--------------------

Baseline characteristics among the patient groups were evaluated. Continuous data are presented as means ± standard deviation or median and 25th to 75th percentiles as appropriate, and compared using one-way analysis of variance or the Wilcoxon rank-sum test, depending on the distribution of variables. Categorical variables are expressed as percentages and evaluated using the chi-squared test. Multiple linear regression analysis was used to determine the relationship between the use of β~2~-agonists, β-blockers, or a combination of both, and indices of cardiac function (NT pro-BNP and LVEF). In the model, we entered "P-in was 0.1 and P-out was 0.05". We entered β-blocker and β~2~-agonist use and factors associated with NT pro-BNP at a *P*-value \< 0.05, using the Enter and Stepwise fashion, included those variables with a *P*-value \< 0.05. The same method was deemed suitable for LVEF. Patient survival was analyzed using the Kaplan--Meier method. The Cox proportional hazard model was used to adjust the variables. Age, body mass index (BMI), blood pressure, heart rate, biochemical markers, echocardiographic parameters, COPD severity, New York Heart Association (NYHA) classification, current smoking status, comorbidities, and prescribed drug use were included in the final model. For all tests, a two-tailed *P*-value \< 0.05 was considered statistically significant. All calculations were performed using SPSS version 16.0 statistical software for Windows (IBM, Armonk, NY, USA).

Results
=======

Baseline characteristics
------------------------

Patient demographics are provided in [Table 1](#t1-cia-8-1157){ref-type="table"}. Data from the 220 enrolled male patients (mean age 84.1 ± 6.9 years) were subjected to statistical analysis. In all, β~2~-agonists were prescribed for 32 patients, β-blockers for 81, both β-blockers and β~2~-agonists for 31, and neither (the control group) for 76.

The patients administered β~2~-agonists had significantly higher predicted FEV~1~ % values (*P* \< 0.001) and had a greater tendency for severe COPD (*P* \< 0.001). Patients treated with β-blockers were more likely to have underlying histories of coronary artery disease and myocardial infarction, whereas those receiving combination therapy had poorer cardiac function status, as indicated by a greater incidence of NYHA classification III (*P* = 0.030). Medication use, age, and current smoking status were similar among the four groups (all *P* \> 0.05). Univariate analysis showed significant differences in both HS-CRP (*P* = 0.030) and LDL-c levels among all four groups. Patients using a combination therapy had significantly higher LDL-c and total cholesterol levels (*P* = 0.006 and 0.020, respectively) compared with other patients. Patients using β~2~-agonists had slightly higher HS-CRP levels (*P* = 0.030) than others ([Table 1](#t1-cia-8-1157){ref-type="table"}).

There was a significant difference in NT pro-BNP values among the four groups, with the highest levels detected in β~2~-agonist users (385.7 pg/mL, range 142.6--960.1; *P* = 0.004). However, differences in LVEF were not statistically significant among the four groups (*P* = 0.108, [Table 1](#t1-cia-8-1157){ref-type="table"}).

Correlation analysis
--------------------

Multivariate linear regression analysis with NT pro-BNP as the dependent variable showed that use of β~2~-agonists (*β* = 35.502, *P* = 0.905), β-blockers (*β* = −3.119, *P* = 0.989), and β-blocker--β~2~-agonist combination therapy (*β* = 298.635, *P* = 0.325) were not significantly associated with NT pro-BNP compared to the control group. Serum creatinine (*β* = 2.954, *P* = 0.017) and the presence of HF (*β* = 746.983, *P* = 0.001) were positively correlated with NT pro-BNP, whereas LDL-c (*β* = −312.188, *P* = 0.017) was negatively correlated with NT pro-BNP. In addition, with LVEF as the dependent variable, there were no significant associations between LVEF and the use of β~2~-agonists (*β* = −0.360, *P* = 0.475), β-blockers (*β* = −0.411, *P* = 0.284), or β-blocker--β~2~-agonist combination therapy (*β* = −0.397, *P* = 0.435). Meanwhile, LVEF was positively associated with shortening fraction (*β* = 1.138, *P* \< 0.001) and negatively associated with left ventricular end-systolic volume (*β* = −0.106, *P* \< 0.001; [Table 2](#t2-cia-8-1157){ref-type="table"}).

Clinical events
---------------

Although a total of 52 patients died over the follow-up period there were no statistical differences in mortality rates among the study groups (*P* = 0.357). NT pro-BNP levels were significantly higher in those patients who died than those who survived (195.7 pg/mL \[range 70.5--449.3\] versus 707.1 pg/mL \[range 194.9--2,393.1\], *P* \< 0.001), but in contrast, LVEF was statistically lower in those patients who died (59.9% ± 6.2% versus 61.4% ± 4.1%, *P* = 0.014). Kaplan--Meier analysis of all-cause mortality revealed no significant difference among the study groups (log-rank test, *P* = 0.362). When adjusted for age, BMI, blood pressure, heart rate, serum creatinine, LDL-c, NT pro-BNP, HS-CRP, echocardiographic parameters, COPD severity, NYHA class, current smoking status, prescribed drugs, and comorbidities, there was still no significant association observed between the use of β~2~-agonists (hazard ratio \[HR\] 0.711, 95% CI 0.287--1.759; *P* = 0.460), β-blockers (HR 0.962, 95% CI 0.405--2.285; *P* = 0.930), or β-blocker--β~2~-agonist combination therapy (HR 0.638, 95% CI 0.241--1.689; *P* = 0.366) and all-cause mortality. In addition, HS-CRP was not associated with mortality (*P* = 0.609) either, whereas NT pro-BNP had a significant effect on mortality (HR 1.612, 95% CI 1.265--2.055; *P* \< 0.001). No statistical interaction was observed between β-blockers and β~2~-agonists regarding all-cause mortality (*P* = 0.428). Multivariable associations of mortality are presented in [Table 3](#t3-cia-8-1157){ref-type="table"}. In addition, among patients receiving beta-blockers, β~2~-agonist use (compared with no β~2~-agonist use) was associated with lower all-cause mortality \[HR 1.134 (0.378--3.403) versus 1.377 (0.485--3.910) in those not receiving a beta-blocker\]. No statistical interaction was observed between β~2~-agonists and β-blockers regarding all-cause mortality ([Table 4](#t4-cia-8-1157){ref-type="table"}).

Discussion
==========

The primary objective of this study was to examine the association between cardiac function, all-cause mortality, and the use of β~2~-agonists, β-blockers, or both in elderly male COPD patients. The main findings of the current study indicated that β~2~-agonist use may not be associated with either NT pro-BNP or LVEF in elderly male COPD patients, and that β~2~-agonist use was not associated either with all-cause mortality in these patients when adjusted for NT pro-BNP, LVEF, and relevant clinical, demographic, and medication variables. Similar results were also found for patients using β-blockers or combination therapy.

Correlation of β~2~-agonist use with cardiac function and mortality
-------------------------------------------------------------------

Unlike some studies that demonstrated that β~2~-agonist use was associated with increased risk of all-cause mortality,[@b13-cia-8-1157],[@b23-cia-8-1157] the present study found that β~2~-agonist use did not influence all-cause mortality in elderly male COPD patients over the follow-up period. Au et al[@b13-cia-8-1157] showed a dose--response increase in mortality in patients with LVSD who used β~2~-agonists. However, they focused on a population with LVSD and did not include patients with HF and preserved systolic function (HFPSF). Another retrospective analysis of the Candesartan in Heart Failure -- Assessment of Reduction in Mortality and Morbidity (CHARM) study examined the effect of bronchodilator use in trial participants. The analysis indicated an increased risk of mortality, cardiovascular death, and major adverse cardiovascular events in bronchodilator users compared to patients not using bronchodilators.[@b23-cia-8-1157] Although previous studies focused on patients with LVSD and/or HFPSF, only a portion of the subjects had coexisting COPD. However, our study included only COPD patients with predominantly normal cardiac function or mild-to-moderate cardiac insufficiency. Furthermore, the incidence of COPD sharply increased with age.[@b1-cia-8-1157] The mean patient age in the two previous studies was less than 70 years, but average patient age in the current study was 84.8 years, which gives more evidence for β~2~-agonist therapy in elderly male COPD patients.

The present study showed that β~2~-agonist use was not associated with either NT pro-BNP or LVEF, which was partially consistent with the finding that chronic β~2~-agonist treatment did not affect LVEF in mice.[@b24-cia-8-1157] In addition, some authors suggested that β~2~-agonists may improve pulmonary function in patients with HF.[@b25-cia-8-1157] Perhaps a plausible hemodynamic explanation is that COPD patients gradually achieved improved right ventricular function and may have achieved improved left ventricular function as well as NT pro-BNP levels to some degree, with ameliorating pulmonary function mediated by β~2~-agonists. Further survival analysis indicated that NT pro-BNP level was an independent risk factor for all-cause mortality. Thus, these data may partly explain why there was no influence of β~2~-agonist use on outcome in our study patients. Bermingham et al[@b10-cia-8-1157] reported that β~2~-agonist therapy in patients with HF showed no relationship with long-time mortality when adjusted for population differences, including BNP levels, which was in accordance with our results. These findings suggested that β~2~-agonists may be used safely in elderly male COPD patients.

Correlation of β-blocker use with cardiac function and mortality
----------------------------------------------------------------

The benefit of β-blocker use in cardiovascular disease with heart dysfunction has been widely accepted in recent years.[@b14-cia-8-1157] Two randomized clinical trials showed a relationship between β-blocker use and cardiac function.[@b26-cia-8-1157],[@b27-cia-8-1157] One showed that carvedilol administration had no influence on plasma NT pro-BNP levels in patients with HF.[@b26-cia-8-1157] In the other study, β-blocker use was associated with increasing LVEF in patients undergoing coronary artery bypass grafting.[@b27-cia-8-1157] However, neither reported an association in COPD patients, especially in high-risk patients, such as the elderly or those with multiple comorbidities for whom physicians may be hesitant to prescribe β-blockers. Our analysis examined this particular patient group, and found that β-blocker use had no association with NT pro-BNP, or LVEF. To elucidate this problem, we next assessed the association between β-blocker use and death from any cause among confirmed COPD patients. The adjusted data confirmed that β-blocker use was not associated with all-cause mortality in elderly male COPD patients, which was consistent with the results of studies that described the beneficial effects of β-blocker use in COPD patients.[@b26-cia-8-1157],[@b27-cia-8-1157] An observational study suggested that β-blocker use had a tendency to lower mortality risk in patients with combined COPD and hypertension.[@b28-cia-8-1157] Also, a recent study produced evidence of the survival benefits of β-blocker use in COPD patients.[@b29-cia-8-1157] Despite the shared viewpoint that caution should be exercised when prescribing β-blockers to COPD patients, the present study demonstrated that even in elderly male COPD patients, β-blocker use may not have an impact on all-cause mortality and may not be contraindicated in older male COPD patients. Thus, we should pay more attention to additional tests.

Correlation of combination therapy with cardiac function and mortality
----------------------------------------------------------------------

The present study is the first to demonstrate that combined use of β-blockers and β~2~-agonists is not associated with NT pro-BNP levels or LVEF in elderly COPD male patients compared to a control group.

Perhaps the most reasonable explanation for this observation is that there was a potential reciprocity between β-blocker and β~2~-agonist use. Some authors have found that β~2~-agonist use may increase cardiac sympathetic outflow and augment ventricular contractility.[@b30-cia-8-1157]--[@b32-cia-8-1157] Beta-blocker use, however, may have a partial antagonistic effect on the inotropic and cardiac sympathetic results of β~2~-agonist use and increased susceptibility to the effects of β~2~-inotropic properties.[@b33-cia-8-1157]--[@b35-cia-8-1157] Newton et al[@b11-cia-8-1157] also observed a significantly less inotropic response to salbutamol in patients treated with β-blockers compared to those not using β-blockers. Together, these studies suggested a pathophysiological and pharmacological plausibility that there may be no influence on cardiac function in elderly COPD patients administered β-blocker and β~2~-agonist combination therapy. Further analysis showed that combination therapy had no influence on all-cause mortality in the fully adjusted model. The results presented here are in line with a large-scale study, which also reported no increased risk of mortality in patients with HF taking both β-blockers and β~2~-agonists.[@b10-cia-8-1157] Two studies that demonstrated that NT pro-BNP was associated with mortality[@b36-cia-8-1157],[@b37-cia-8-1157] were also consistent with our results. However, unlike the previous large-scale study study, we focused on COPD patients who were almost 10 years older. This new information may provide important evidence and background information for further prospective studies.

Our results showed that β~2~-agonist users had a higher incidence of severe COPD and higher HS-CRP levels, which was consistent with an observation that COPD severity was correlated with CRP.[@b38-cia-8-1157] However, after full adjustment, there was no significant association between HS-CRP and mortality. Therefore, this finding suggested that β~2~-agonist use may have no influence on mortality in elderly male COPD patients.

To our knowledge, different drugs have different chemical formulas, which could cause a potential discrepancy in the mode of action. In the current study, no significant difference was observed in medication use at baseline, such as loop diuretics and calcium-channel blockers. However, our results may not reflect the discrepancy on different kinds of β-blockers/β~2~-agonists. Thus, further prospective studies on the issue are needed to validate these early findings.

There were some limitations to the present study. First, all patients were male and the study population was relatively small. Further large-scale studies (including female patients) are required to verify the findings of the present study. Second, the specific type, administration route, dose, frequency, and duration of therapy were not recorded. It was also difficult to adjust adequately for measurement of patient adherence. Third, this was an observational, retrospective, cohort study and not a large-scale, prospective, randomized trial; therefore, the lack of association we observed cannot be assessed definitively. However, the information regarding β-blocker use was based on prescription records and clinic data, all of the included patients were carefully examined, data were obtained on lung-function measurements and demographic information, and sophisticated statistical modeling was performed. Given that the prevalence of COPD increases with age and most of the patients were male,[@b2-cia-8-1157],[@b3-cia-8-1157] the present study may at least give some implications for COPD management and timely initiation of disease-modifying therapy in elderly male patients.

Conclusion
==========

In summary, the present study showed no significant association between the administration of β~2~-agonists, β-blockers, or a β-blocker--β~2~-agonist combination therapy and cardiac function as well as all-cause mortality in elderly male COPD patients, thus these medications may be used safely in elderly male COPD patients. Our results may be helpful to assess the clinical effectiveness of β~2~-agonist and β-blocker use in such patients; however, additional prospective studies are required to validate our findings.
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###### 

Baseline characteristics

  Characteristic                    β~2~-agonists (n = 32)   β-blockers (n = 81)    β-blockers + β-agonists (n = 31)   Control (n = 76)       *P*-value
  --------------------------------- ------------------------ ---------------------- ---------------------------------- ---------------------- -----------
  Demographics                                                                                                                                
   Age (years)                      84.8 ± 6.4               84.6 ± 6.2             86.0 ± 4.6                         82.6 ± 8.5             0.135
  COPD severity                                                                                                                               
   FEV~1~, predicted (%)            58.9 ± 21.6              80.4 ± 19.9            74.7 ± 18.0                        81.6 ± 22.7            \<0.001
   FEV~1~/FVC (%)                   50.6 ± 11.5              62.7 ± 6.7             56.5 ± 9.6                         60.7 ± 8.5             \<0.001
   Mild, n (%)                      3 (9.4)                  41 (50.6)              12 (38.7)                          44 (57.9)              \<0.001
   Moderate, n (%)                  17 (53.1)                36 (44.4)              17 (54.8)                          27 (35.5)              0.192
   Severe, n (%)                    12 (37.5)                4 (4.9)                2 (6.5)                            5 (6.6)                \<0.001
  Cardiovascular history                                                                                                                      
   Coronary artery disease, n (%)   21 (65.6)                70 (86.4)              26 (83.9)                          48 (69.2)              0.001
   Heart failure, n (%)             9 (28.1)                 19 (23.5)              9 (29.0)                           13 (17.1)              0.616
  NYHA functional class, n (%)                                                                                                                
   NYHA I                           20 (62.5)                55 (67.9)              17 (54.8)                          60 (78.9)              0.068
   NYHA II                          9 (28.1)                 19 (23.5)              9 (29.0)                           14 (18.4)              0.575
   NYHA III                         3 (9.4)                  7 (8.6)                6 (19.4)                           2 (2.6)                0.030
   Myocardial infarction            0 (0.0)                  11 (13.6)              3 (9.7)                            1 (1.3)                0.004
  Clinical characteristics                                                                                                                    
   BMI (kg/m^2^)                    22.7 ± 3.1               24.7 ± 2.6             23.9 ± 2.9                         24.1 ± 3.0             0.009
   Systolic BP (mmHg)               130.1 ± 16.7             131.9 ± 16.4           130.4 ± 11.4                       129.1 ± 15.1           0.927
   Diastolic BP (mmHg)              67.4 ± 8.7               70.1 ± 10.8            66.8 ± 8.7                         69.8 ± 9.8             0.292
   Heart rate (bpm)                 78.2 ± 16.3              72.7 ± 12.4            74.0 ± 7.5                         71.3 ± 9.9             0.068
   Current smoker, n (%)            9 (28.1)                 25 (30.9)              8 (25.8)                           29 (38.2)              0.573
   Hypertension, n (%)              25 (78.1)                61 (75.3)              25 (80.6)                          52 (68.4)              0.544
   Diabetes mellitus, n (%)         12 (37.5)                39 (48.1)              16 (51.6)                          32 (42.1)              0.611
   Dyslipidemia, n (%)              4 (12.5)                 17 (21.0)              6 (19.4)                           19 (25.0)              0.565
   Atrial fibrillation, n (%)       5 (15.6)                 15 (18.5)              6 (19.4)                           7 (9.2)                0.304
   PAOD, n (%)                      3 (9.4)                  22 (27.2)              6 (19.4)                           12 (15.8)              0.132
   Renal dysfunction, n (%)         4 (30.8)                 21 (41.2)              4 (20.0)                           11 (34.4)              0.417
  Concomitant therapy, n (%)                                                                                                                  
   ACE inhibitors                   3 (9.4)                  13 (16.0)              4 (12.9)                           4 (5.3)                0.167
   A2RAs                            9 (28.1)                 30 (37.0)              11 (35.5)                          22 (28.9)              0.666
   Calcium-channel blockers         21 (65.6)                49 (60.5)              20 (64.5)                          42 (55.3)              0.711
   Loop diuretics                   11 (34.4)                26 (32.1)              14 (45.2)                          19 (25.0)              0.234
   Antiplatelet                     22 (68.8)                51 (63.0)              19 (61.3)                          49 (64.5)              0.929
   Statins                          15 (46.9)                45 (55.6)              12 (38.7)                          37 (48.7)              0.439
   Digoxin                          5 (15.6)                 7 (8.6)                4 (12.9)                           6 (7.9)                0.538
   Nitrates                         22 (68.8)                50 (61.7)              20 (64.5)                          44 (57.9)              0.758
   Spironolactone                   4 (12.5)                 9 (11.1)               3 (9.7)                            5 (6.6)                0.714
  Laboratory parameters                                                                                                                       
   NT pro-BNP (pg/mL)               385.7 (142.6--960.1)     226.2 (116.3--718.9)   272.1 (113.1--152.6)               112.6 (71.9--379.1)    0.004
   Serum creatinine (μmol/L)        97.5 (70.1--127.7)       93.0 (75.3--126.9)     95.0 (74.0--133.0)                 88.9 (75.8--113.3)     0.643
   Uric acid (mmol/L)               313.7 (253.5--373.0)     331.4 (266.0--381.1)   353.2 (276.2--453.5)               317.5 (260.7--373.4)   0.282
   HS-CRP (mg/dL)                   0.84 (0.3--2.9)          0.4 (0.1--0.8)         0.7 (0.3--2.3)                     0.6 (0.2--1.9)         0.030
   Total cholesterol (mmol/L)       3.9 (3.7--4.8)           3.7 (3.3--4.4)         4.5 (4.0--4.9)                     4.3 (3.61--4.87)       0.020
   Triglyceride (mmol/L)            1.2 (0.8--1.6)           1.3 (0.9--1.7)         1.6 (1.0--1.9)                     1.2 (0.9--1.8)         0.319
   HDL-c (mmol/L)                   1.3 (1.0--1.4)           1.1 (0.9--1.3)         1.1 (0.9--1.4)                     1.1 (0.9--1.4)         0.229
   LDL-c (mmol/L)                   2.1 (1.8--2.6)           2.1 (1.7--2.7)         2.7 (2.4--3.2)                     2.4 (2.0--3.1)         0.006
   Serum glucose (mmol/L)           5.7 (4.9--6.2)           5.7 (5.0--6.4)         5.5 (4.7--6.6)                     5.6 (5.1--6.1)         0.931
  Echocardiographic parameters                                                                                                                
   LVESV (mL)                       39.7 ± 7.5               46.4 ± 12.6            44.3 ± 8.4                         43.1 ± 8.7             0.018
   LVEDV (mL)                       106.6 ± 16.8             115.5 ± 21.8           113.9 ± 14.7                       111.9 ± 16.0           0.131
   Shortening fraction (%)          34.2 ± 2.2               32.6 ± 3.2             32.7 ± 3.3                         33.2 ± 2.5             0.055
   LVEF (%)                         62.6 ± 3.1               60.1 ± 5.9             60.5 ± 4.6                         61.6 ± 3.4             0.108
    \<50%, n (%)                    0 (0.0)                  4 (4.9)                1 (3.2)                            0 (0.0)                
    \>50%, n (%)                    32 (100)                 77 (95.1)              30 (96.8)                          76 (100.0)             

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NYHA, New York Heart Association; BMI, body mass index; BP, blood pressure; bpm, beats per minute; PAOD, peripheral arterial occlusive disease; ACE, angiotensin-converting enzyme; A2RA, angiotensin-II receptor antagonist; HS-CRP, high-sensitivity C-reactive protein; LDL-c, low-density-lipoprotein cholesterol; HDL-c, high-density-lipoprotein cholesterol; NT pro BNP, N-terminal pro-hormone brain natriuretic parameters; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction.

###### 

Linear regression analyses of clinical data, echocardiographic data and NT pro-BNP/LVEF

  Characteristic               Model 1    Model 2                             
  ---------------------------- ---------- --------- ------- -------- -------- ---------
  β~2~-agonists                35.502     0.120     0.905   −0.360   −0.715   0.475
  β-blockers                   −3.119     −0.013    0.989   −0.411   −1.074   0.284
  β-blockers + β~2~-agonists   298.635    0.986     0.325   −0.397   −0.783   0.435
  Heart failure                746.983    3.533     0.001   --       --       --
  Serum creatinine             2.954      2.407     0.017   --       --       
  LDL-c                        −312.188   −2.408    0.017   --       --       --
  Shortening fraction          --         --        --      1.138    16.148   \<0.001
  LVESV                        --         --        --      −0.106   −5.337   \<0.001

**Abbreviations:** NT pro-BNP, N-terminal pro-hormone brain natriuretic parameters; LVEF, left ventricular ejection fraction; LDL-c, low-density-lipoprotein cholesterol; LVESV, left ventricular end-systolic volume.

###### 

Associates of all-cause mortality in the total population

  Variable                     HR (95% CI, *P*-value)
  ---------------------------- -------------------------------
  NT pro-BNP                   1.612 (1.265--2.055, \<0.001)
  Myocardial infarction        4.026 (1.229--13.187, 0.021)
  Renal dysfunction            2.363 (1.229--4.544, 0.010)
  ACE inhibitors               0.155 (0.035--0.689, 0.014)
  A2RAs                        0.387 (0.181--0.828, 0.014)
  Loop diuretic                3.973 (2.004--7.877, \<0.001)
  β~2~-agonists                0.711 (0.287--1.759, 0.460)
  β-blockers                   0.962 (0.405--2.285, 0.930)
  β-blockers + β~2~-agonists   0.638 (0.241--1.689, 0.366)

**Abbreviations:** HR, hazard ratio; CI, confidence interval; NT-proBNP, N-terminal pro-hormone brain natriuretic parameters; ACE, angiotensin-converting enzyme; A2RA, angiotensin-II receptor antagonist.

###### 

Association between β~2~-agonist use and all-cause mortality according to β-blocker therapy

  Outcome, β-blockers   β~2~-agonists   No β~2~-agonists   HR (95% CI)            *P*-value   *P*-value interaction[a](#tfn4-cia-8-1157){ref-type="table-fn"}
  --------------------- --------------- ------------------ ---------------------- ----------- -----------------------------------------------------------------
  β-blockers            31              81                 1.134 (0.378--3.403)   0.823       0.428
  No β-blockers         32              76                 1.377 (0.485--3.910)   0.548       

**Note:**

Interaction between β~2~-agonists and β-blockers.

**Abbreviations:** HR, hazard ratio; CI, confidence interval.

[^1]: \*These authors contributed equally to this work
